Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCURAY INCARAY · Entity 1170 | Director | November 28, 2025 | December 02, 2025 |
| Sienna Biopharmaceuticals, Inc.SNNA · Entity 154554 | Director | May 30, 2019 | June 03, 2019 |
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Director | June 22, 2020 | June 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCURAY INC
Report date November 28, 2025 · Filed December 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 56,603 |
Reported balance
After 2025-11-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-28 · Grant · Acquired 56,603 · Balance 56,603 F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2: This represents a Restricted Stock Unit that vests 100% on 11/13/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: This represents a Restricted Stock Unit that vests 100% on 11/13/2026.
Sienna Biopharmaceuticals, Inc.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2029-05-30 | Direct | 25,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date.
Tempest Therapeutics, Inc.
Report date June 22, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2030-06-21 | Direct | 12,000 |
Reported balance
After 2020-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-22 · Grant · Acquired 12,000 · Balance 12,000 F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Urovant Sciences Ltd.
Report date March 29, 2021 · Filed March 31, 2021
Section 16 reporting ended · disclosed 2021-03-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-03-29 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in common shares of the Issuer ("Common Shares") prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.53 · Expires 2030-06-01 | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-29 · Disposition to issuer · Disposed 61,000 · Balance 0 F2: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2030-07-21 | Direct | 0 |
Reported balance
After 2021-03-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-29 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in common shares of the Issuer ("Common Shares") prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
F2: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 28, 2025 Filed Dec 2, 2025 22:25 UTC | ACCURAY INC ARAY · Entity 1170 | GrantRestricted Stock Units · Derivative | 56,603 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-017516 · marketforms-71395.xml · derivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,603 Underlying: Common Stock · 56,603 shares Expires not disclosed F1 · security: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: This represents a Restricted Stock Unit that vests 100% on 11/13/2026. F2 · derivative.expiration_date: This represents a Restricted Stock Unit that vests 100% on 11/13/2026. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 22:55 UTC | ACCURAY INC ARAY · Entity 1170 | Exercise / conversionRestricted Stock Units · Derivative | 56,603 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-017241 · marketforms-71314.xml · derivative · entry 2 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,603 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: This represents a Restricted Stock Unit that vests 100% on 11/21/2025. F2 · derivative.expiration_date: This represents a Restricted Stock Unit that vests 100% on 11/21/2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 22:55 UTC | ACCURAY INC ARAY · Entity 1170 | Exercise / conversionCommon Stock | 56,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-017241 · marketforms-71314.xml · nonDerivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 21:20 UTC | ACCURAY INC ARAY · Entity 1170 | GrantRestricted Stock Units · Derivative | 56,603 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-019900 · marketforms-67456.xml · derivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,603 Underlying: Common Stock · 56,603 shares Expires not disclosed F1 · security: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: This represents a Restricted Stock Unit that vests 100% on 11/21/2025. F2 · derivative.expiration_date: This represents a Restricted Stock Unit that vests 100% on 11/21/2025. Read SEC document |
| November 30, 2023 Filed Dec 5, 2023 01:50 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 56,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-016004 · marketforms-63679.xml · nonDerivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,201 F1 · shares: This represents a Restricted Stock Unit that vests 100% on 11/9/2024. Read SEC document |
| November 30, 2022 Filed Dec 7, 2022 21:35 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 59,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-014648 · marketforms-57817.xml · nonDerivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,598 F1 · shares: This represents a Restricted Stock Unit that vest 100% on 11/10/2023. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 22:00 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 31,185 | $4.81 | $149,999.85 |
DisclosureSEC source: 0001214659-21-012598 · marketforms-54456.xml · nonDerivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,543 F1 · shares: This represents a Restricted Stock Unit that vest 100% on 11/19/2022. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0000899243-21-014105 · doc4.xml · derivative · entry 3 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 15,000 shares Expires 2030-07-21 F2 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerStock Option (Right to Buy) · Derivative | 61,000 | $0.00 Strike: $10.53 | $0.00 |
DisclosureSEC source: 0000899243-21-014105 · doc4.xml · derivative · entry 2 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 61,000 shares Expires 2030-06-01 F2 · derivative.exercise_date: Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| March 29, 2021 Filed Mar 31, 2021 12:30 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | Disposition to issuerCommon Shares | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-014105 · doc4.xml · nonDerivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in common shares of the Issuer ("Common Shares") prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. F1 · price: Immediately prior to the consummation of the Merger, these securities were time-based restricted share units ("RSUs") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan. Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in common shares of the Issuer ("Common Shares") prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:15 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 33,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001138723-20-000098 · edgardoc.xml · nonDerivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,358 F1 · shares: This represents a Restricted Stock Unit that vest 100% on 11/20/2021. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 16:35 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001209191-20-043489 · doc4.xml · derivative · entry 2 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2030-07-21 F2 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable on July 21, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 16:35 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantCommon Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043489 · doc4.xml · nonDerivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: The Restricted Stock Units shall vest on July 21, 2021, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 11:05 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001544227-20-000029 · wf-form4_159291030142413.xml · derivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-21 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. Read SEC document |
| June 01, 2020 Filed Jun 1, 2020 18:05 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 61,000 | $0.00 Strike: $10.53 | $0.00 |
DisclosureSEC source: 0001209191-20-033291 · doc4.xml · derivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,000 Underlying: Common Shares · 61,000 shares Expires 2030-06-01 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in three equal annual installments beginning on June 1, 2021, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 22:49 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 48,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001138723-19-000068 · edgardoc.xml · nonDerivative · entry 2 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,726 F3 · kind: All of the restricted stock units vest on November 21, 2020. F2 · shares: This grant is represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of ARAY common stock. Read SEC document |
| September 30, 2019 Filed Dec 3, 2019 22:49 UTC | ACCURAY INC ARAY · Entity 1170 | GrantCommon Stock | 9,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001138723-19-000068 · edgardoc.xml · nonDerivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,025 F1 · kind: The restricted stock unit granted on 09/30/2019 released as scheduled on 11/18/2019. F2 · shares: This grant is represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of ARAY common stock. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:37 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001209191-19-038482 · doc4.xml · derivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on June 20, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 19:32 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 25,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001562180-19-003240 · primarydocument.xml · derivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:47 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-19-004239 · doc4.xml · derivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on January 15, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:41 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 3,720 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0001209191-18-062117 · doc4.xml · derivative · entry 2 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,720 Underlying: Common Stock · 3,720 shares Expires 2028-08-23 F4 · price: Received in connection with the Merger in exchange for a stock option to acquire 50,000 shares of Millendo common stock for $1.22 per share. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:41 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 17,509 | Not disclosed Strike: $6.59 | Not disclosed |
DisclosureSEC source: 0001209191-18-062117 · doc4.xml · derivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,509 Underlying: Common Stock · 17,509 shares Expires 2026-08-09 F2 · price: Received in connection with the merger of Millendo Therapeutics, Inc. ("Millendo") into the Issuer (the "Merger") in exchange for a stock option to acquire 235,341 shares of Millendo common stock for $0.49 per share. F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on June 17, 2017, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 17:53 UTC | Sienna Biopharmaceuticals, Inc. SNNA · Entity 154554 | GrantStock Options (Right to buy) · Derivative | 20,000 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0001562180-18-003485 · primarydocument.xml · derivative · entry 1 Hindman James M. · CIK 0001617615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-08-01 F1 · derivative.exercise_date: The option vests with respect to 1/36th of the shares subject thereto on each monthly anniversary of the grant date, subject to continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.